| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/18/2006 | CA2586479A1 Lipase inhibitors |
| 05/18/2006 | CA2586459A1 Therapeutic agent for interstitial cystitis |
| 05/18/2006 | CA2586446A1 Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof |
| 05/18/2006 | CA2586375A1 Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
| 05/18/2006 | CA2586370A1 Constrained compounds as cgrp-receptor antagonists |
| 05/18/2006 | CA2586355A1 Derivatives of 4,7-dioxobenzothiazole-2-carboxamides, preparation method thereof and therapeutic uses of same |
| 05/18/2006 | CA2586316A1 Pyrimidine compounds as histamine modulators |
| 05/18/2006 | CA2586195A1 Treatment of acne using derivatives of 5-aminolevulinic acid |
| 05/18/2006 | CA2586156A1 Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| 05/18/2006 | CA2586135A1 Compositions and processes for preparing 13-deoxy-anthracyclines |
| 05/18/2006 | CA2586124A1 Formulations of [1,4]diazepino[6,7,1-ij]quinoline derivatives |
| 05/18/2006 | CA2586122A1 Metabolites of certain [1,4]diazepino[6,7,1-ij]quinoline derivatives and methods of preparation and use thereof |
| 05/18/2006 | CA2586106A1 Sulfamides as endothelin receptor antagonists for the treatment of cardiovascular diseases |
| 05/18/2006 | CA2586105A1 Aminoquinazolines compounds |
| 05/18/2006 | CA2586068A1 Dibenzosuberone derivatives |
| 05/18/2006 | CA2585983A1 Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases |
| 05/18/2006 | CA2585976A1 Novel composition for easing human childbirth |
| 05/18/2006 | CA2585797A1 Lactam compounds and their use as pharmaceuticals |
| 05/18/2006 | CA2585664A1 Biodegradable linkers for molecular therapies |
| 05/18/2006 | CA2585660A1 1,4 substituted pyrazolopyrimidines as kinase inhibitors |
| 05/18/2006 | CA2585654A1 Use of acetyl l-carnitine in combination with propionyl l-carnitine and sildenafil for the treatment of erectile dysfunction |
| 05/18/2006 | CA2585490A1 Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
| 05/18/2006 | CA2585446A1 Improved dosing regimen of temozolomide for treating cancer based on the patient's mgmt level |
| 05/18/2006 | CA2585315A1 Imidazo[1,2-a]pyridine compounds, compositions, uses and methods related thereto |
| 05/18/2006 | CA2585314A1 A process for preparing formulations of lipophilic active substances by spray freeze drying |
| 05/18/2006 | CA2585310A1 5-heteroaryl thiazoles and their use as p13k inhibitors |
| 05/18/2006 | CA2585296A1 Stabilized freeze-dried formulation for cephalosporin derivatives |
| 05/18/2006 | CA2585165A1 Dual antiplatelet/anticoagulant pyridoxine analogs |
| 05/18/2006 | CA2584586A1 Hydroxybenzoate salts of metanicotine compounds |
| 05/18/2006 | CA2584475A1 Extended surface aggregates in the treatment of skin conditions |
| 05/18/2006 | CA2584448A1 Hydroxybenzoate salts of metanicotine compounds |
| 05/18/2006 | CA2584286A1 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses |
| 05/18/2006 | CA2584279A1 Compositions and methods for stabilizing liposomal drug formulations |
| 05/18/2006 | CA2584225A1 Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists |
| 05/18/2006 | CA2584017A1 Aqueous ophthalmic suspension of crystalline rebamipide |
| 05/18/2006 | CA2583761A1 Herbal composition phy906 and its use in chemotherapy |
| 05/18/2006 | CA2583187A1 Method for treating hiv infection through co-administration of tipranavir and etravirine |
| 05/18/2006 | CA2576279A1 Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders |
| 05/18/2006 | CA2575668A1 Azaindole carboxamides |
| 05/18/2006 | CA2574326A1 Novel form of celecoxib |
| 05/18/2006 | CA2488113A1 A non-human animal alzheimer's disease model and uses thereof |
| 05/17/2006 | EP1657954A1 Transmitter of wireless microphone, receiver for wireless microphone, mobile information communication apparatus, and communication system for wireless microphone |
| 05/17/2006 | EP1657256A2 Compositions and methods for the treatment of tumor |
| 05/17/2006 | EP1657247A1 Steroidal compounds for inhibiting steroid sulphotase |
| 05/17/2006 | EP1657244A1 2-thiaquinolizidines as glycosidase and glycosyltransferase inhibitors |
| 05/17/2006 | EP1657242A1 Imidazopyridine derivatives |
| 05/17/2006 | EP1657241A1 Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| 05/17/2006 | EP1657238A1 Fused pyrimidine derivative and use thereof |
| 05/17/2006 | EP1657233A1 Lipoxin compounds |
| 05/17/2006 | EP1657232A1 Use of S-enantiomers of alpha-sustituted aryl acetic acids for the prevention of Alzheimer's disease |
| 05/17/2006 | EP1656942A2 Isoflavone-containing composition |
| 05/17/2006 | EP1656941A1 Compositions for the treatment of diabetic nephropathy |
| 05/17/2006 | EP1656940A1 Angiotensin II receptor antagonists for treating vascular headache conditions |
| 05/17/2006 | EP1656939A1 Use of melatonin in the manufacture of a medicament for treating cancer |
| 05/17/2006 | EP1656938A1 Combinations of SSRI and estrogenic agents |
| 05/17/2006 | EP1656937A1 The use of mirtazapine for the treatment of sleep disorders |
| 05/17/2006 | EP1656936A1 Macrophage activation inhibitor |
| 05/17/2006 | EP1656935A1 Use of physiologically active fatty acids for the treatment of pruritus |
| 05/17/2006 | EP1656934A1 Use of physiologically active fatty acids for treating lipodystrophy |
| 05/17/2006 | EP1656933A1 A medicinal composition comprising L-alanine for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis and use therof |
| 05/17/2006 | EP1656932A1 Material for aneurysm curing |
| 05/17/2006 | EP1656931A1 Compounds which inhibits protein prenylation ( e.g. geranylgeranyltransferase or farnesyltransferase inhibitors) for treating Parkinson's disease |
| 05/17/2006 | EP1656930A1 Stabilized freeze-dried formulation for cephalosporin derivatives |
| 05/17/2006 | EP1656839A1 Nutrition containing lipid blend |
| 05/17/2006 | EP1656454A2 Methionine recovery processes |
| 05/17/2006 | EP1656387A2 Nucleobase phosphonate analogs for antiviral treatment |
| 05/17/2006 | EP1656380A2 7-polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups |
| 05/17/2006 | EP1656379A1 4-cycloalkylaminopyrazolo pyrimidine nmda/nr2b antagonists |
| 05/17/2006 | EP1656378A2 Compounds and compositions as inhibitors of receptor tyrosine kinase activity |
| 05/17/2006 | EP1656372A2 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| 05/17/2006 | EP1656371A2 Novel oxazoles, their manufacture and use as pharmaceutical agents |
| 05/17/2006 | EP1656370A2 Biaryl heterocyclic compounds and methods of making and using the same |
| 05/17/2006 | EP1656368A2 Substituted hertocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| 05/17/2006 | EP1656359A2 Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease |
| 05/17/2006 | EP1656358A2 Stable polymorph of bifeprunox mesilate |
| 05/17/2006 | EP1656355A2 Piperazine derivatives and methods of use |
| 05/17/2006 | EP1656353A1 Gabanergic modulators |
| 05/17/2006 | EP1656349A1 Cyclopropyl derivatives as nk3 receptor antagonists |
| 05/17/2006 | EP1656348A1 Acetylene derivatives as inhibitors of histone deacetylase |
| 05/17/2006 | EP1656346A1 Novel substituted 3-sulfur indoles |
| 05/17/2006 | EP1656339A1 Polymorphic forms of nateglinide |
| 05/17/2006 | EP1656183A1 Treatment of male sexual dysfunction |
| 05/17/2006 | EP1656157A1 2-methylene-19-nor-vitamin d2 compounds |
| 05/17/2006 | EP1656156A2 Mobilization of hematopoietic cells |
| 05/17/2006 | EP1656152A1 Composition and method for treating upper abdominal pain and cramping |
| 05/17/2006 | EP1656147A1 Diflunisal for the treatment of cancer |
| 05/17/2006 | EP1656146A2 Mitotic kinesin inhibitors |
| 05/17/2006 | EP1656144A2 Trp-p8 active compounds and therapeutic treatment methods |
| 05/17/2006 | EP1656143A2 Novel use of quinolone antibiotics |
| 05/17/2006 | EP1656142A2 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds |
| 05/17/2006 | EP1656141A1 Treatment for alzheimer s disease and related conditions |
| 05/17/2006 | EP1656140A1 Mitotic kinesin inhibitors |
| 05/17/2006 | EP1656139A1 Aryl dicarboxamides |
| 05/17/2006 | EP1656138A2 Substituted cycloalkyamine derivatives as modulators of chemokine receptor activity |
| 05/17/2006 | EP1656137A1 Channel blocking compounds |
| 05/17/2006 | EP1656135A1 Method and composition for treating burned skin |
| 05/17/2006 | EP1656133A2 Mitotic kinesin inhibitors |
| 05/17/2006 | EP1656131A2 Use of betaine for treating arteritis |
| 05/17/2006 | EP1656130A1 Omega-3 fatty acids for the treatment of canine ostheoarthritis |
| 05/17/2006 | EP1656129A2 Blockade of mtor to prevent a hormonal adaptive response |